These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 24329524

  • 1. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.
    Vora J, Caputo S, Damci T, Orozco-Beltran D, Pan C, Svendsen AL, Sølje KS, Khunti K, SOLVE study group.
    J Clin Pharm Ther; 2014 Apr; 39(2):136-43. PubMed ID: 24329524
    [Abstract] [Full Text] [Related]

  • 2. Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice.
    Ross S, Dzida G, Ji Q, Kaiser M, Ligthelm R, Meneghini L, Nazeri A, Orozco-Beltran D, Pan C, Svendsen AL, SOLVE Study Group.
    J Diabetes; 2014 May; 6(3):243-50. PubMed ID: 24103141
    [Abstract] [Full Text] [Related]

  • 3. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
    Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H.
    Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775
    [Abstract] [Full Text] [Related]

  • 4. The association between adherence to oral anti-diabetic drugs and hypoglycaemia in persons with Type 2 diabetes.
    Quilliam BJ, Ozbay AB, Sill BE, Kogut SJ.
    Diabet Med; 2013 Nov; 30(11):1305-13. PubMed ID: 23586474
    [Abstract] [Full Text] [Related]

  • 5. Weight-neutral effect of once-daily insulin detemir in Chinese type 2 diabetes patients: subgroup analysis of the SOLVE study.
    Pan C, Han P, Ji L, Ji Q, Lu J, Lin J, Liu J, Su B, Shi J, Wang P.
    J Diabetes; 2015 Mar; 7(2):222-30. PubMed ID: 24909984
    [Abstract] [Full Text] [Related]

  • 6. Safety and effectiveness of insulin detemir in combination with oral antidiabetic agents in an outpatient specialist setting: results of the Italian SOLVE™ observational study.
    Caputo S, Maran A, Mannino D, Morano S, Lastoria G, Nicoziani P.
    Minerva Endocrinol; 2015 Dec; 40(4):249-58. PubMed ID: 26551483
    [Abstract] [Full Text] [Related]

  • 7. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ, Bailey CJ.
    Drugs; 2005 Dec; 65(3):385-411. PubMed ID: 15669880
    [Abstract] [Full Text] [Related]

  • 8. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R, Gruenberger JB, Bader G, Dworak M.
    Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
    [Abstract] [Full Text] [Related]

  • 9. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
    Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ.
    Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
    [Abstract] [Full Text] [Related]

  • 10. Study of Once Daily Levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice.
    Khunti K, Damci T, Meneghini L, Pan CY, Yale JF, SOLVE Study Group.
    Diabetes Obes Metab; 2012 Jul; 14(7):654-61. PubMed ID: 22443213
    [Abstract] [Full Text] [Related]

  • 11. Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control.
    Grimm M, Li Y, Brunell SC, Blase E.
    Postgrad Med; 2013 Sep; 125(5):101-8. PubMed ID: 24113668
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).
    Pratley RE, Urosevic D, Boldrin M, Balena R, T-emerge 6 Study Group.
    Diabetes Obes Metab; 2013 Mar; 15(3):234-40. PubMed ID: 22958426
    [Abstract] [Full Text] [Related]

  • 13. [Effectiveness and safety of initiation of once-daily insulin detemir in Chinese patients with type 2 diabetes previously treated with different quantities of oral anti-diabetic drugs: subgroup analysis of the Chinese SOLVE™ Study].
    Pan C, Ji L, Lu J, Yang W, Zhou Z, Chinese SOLVE™ Study.
    Zhonghua Nei Ke Za Zhi; 2015 Jul; 54(7):612-7. PubMed ID: 26359024
    [Abstract] [Full Text] [Related]

  • 14. Severe hypoglycemia is associated with antidiabetic oral treatment compared with insulin analogs in nursing home patients with type 2 diabetes and dementia: results from the DIMORA study.
    Abbatecola AM, Bo M, Barbagallo M, Incalzi RA, Pilotto A, Bellelli G, Maggi S, Paolisso G, Italian Society of Gerontology and Geriatrics (SIGG), Florence, Italy.
    J Am Med Dir Assoc; 2015 Apr; 16(4):349.e7-12. PubMed ID: 25669671
    [Abstract] [Full Text] [Related]

  • 15. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
    Dornhorst A, Lüddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ, Meneghini L, PREDICTIVE Study Group.
    Int J Clin Pract; 2008 Apr; 62(4):659-65. PubMed ID: 18324957
    [Abstract] [Full Text] [Related]

  • 16. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
    Fonseca V, Gill J, Zhou R, Leahy J.
    Diabetes Obes Metab; 2011 Sep; 13(9):814-22. PubMed ID: 21481127
    [Abstract] [Full Text] [Related]

  • 17. Appropriate insulin initiation dosage for insulin-naive type 2 diabetes outpatients receiving insulin monotherapy or in combination with metformin and/or pioglitazone.
    Liao L, Yang M, Qiu LL, Mou YR, Zhao JJ, Dong JJ.
    Chin Med J (Engl); 2010 Dec; 123(24):3684-8. PubMed ID: 22166651
    [Abstract] [Full Text] [Related]

  • 18. Guideline-conformity of initiation with oral hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria.
    Winkelmayer WC, Stedman MR, Pogantsch M, Wieninger P, Bucsics A, Asslaber M, Bauer R, Burkhardt T, Schautzer A, Brookhart MA, Pharmacoeconomics Advisory Council of the Main Association of Austrian Sickness Funds.
    Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):57-65. PubMed ID: 21182153
    [Abstract] [Full Text] [Related]

  • 19. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.
    Rascati K, Richards K, Lopez D, Cheng LI, Wilson J.
    Diabetes Obes Metab; 2013 Oct; 15(10):901-5. PubMed ID: 23531154
    [Abstract] [Full Text] [Related]

  • 20. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
    Prescrire Int; 2005 Oct; 14(79):187-93. PubMed ID: 16285076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.